logo-loader

Algernon Pharma hits milestone in Phase 2b/3 human study of Ifenprodil enrolling 154th patient

Published: 11:55 23 Nov 2020 EST

Algernon Pharmaceuticals (CSE:AGN-OTCQB: AGNPF) CEO Christopher Moreau joined Steve Darling from Proactive to bring news the company has now enrolled 154 patients in its multinational Phase 2b/3 human study of Ifenprodil) for the treatment of COVID-19.

Moreau telling Proactive they have increased the number of patients involved in the study and also gave some details about how the study is being conducted.

Algernon Pharmaceuticals Strikes Deal to Advance Ifenprodil in Chronic Cough...

Algernon Pharmaceuticals CEO Christopher Moreau joined Steve Darling from Proactive to announce a significant agreement regarding the company's drug, Ifenprodil with U.S. Based Seyltx. Originally discovered in Japan and not utilized in the US or Europe, Ifenprodil was initially developed to...

21 hours, 4 minutes ago